All In Biotech

Drug Trial Radar · NCT06747338

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

Dec 16, 2026

Study completion Dec 16, 2027

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.

Conditions

  • Early or Locally Advanced HER2-positive Breast Cancer

Interventions

  • KN026Drug

    KN026

  • HB1801Drug

    HB1801

  • PertuzumabDrug

    Pertuzumab

  • TrastuzumabDrug

    Trastuzumab

  • DocetaxelDrug

    Docetaxel

  • CarboplatinDrug

    Carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. tpCR (BIRC, AJCC 8th)Time frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Information Group

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.